Covista stock gains 13% as enrollment growth beats expectations. 09 August 2026 12:21 PM PDT Summarize with AI You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to its research reports, in-depth technical and fundamental research. Learn more Key Highlights - CVSA shares surged approximately 13.46 percent to $140.98, a gain of $16.72 from a prior close of $124.26. - Fiscal fourth quarter adjusted EPS of $2.09 beat the $1.89 expected, with revenue of $501.4 million topping the $494.9 million estimate. - The company issued fiscal 2027 guidance for revenue between $2.05 billion and $2.09 billion, both above and slightly above analyst estimates. - The company returned $238 million to shareholders via buybacks, while issuing fiscal 2027 guidance for continued growth. Fiscal Q4 Beat Across Metrics Covista Inc. (NYSE:CVSA), formerly Adtalem Global Education Inc., America's largest healthcare educator serving over 100,000 students across accredited institutions including Chamberlain, Ross University, and Walden University, closed up 13.46 percent at $140.98 after fiscal fourth quarter results beat estimates, with adjusted EPS of $2.09 versus $1.89 expected and revenue of $501.4 million topping the $494.9 million estimate. The company also reported full-year adjusted EPS of $8.30 and revenue growth gains. Both Walden and Chamberlain segments contributed to the beat, with enrollment growth and record enrollments at both institutions cited as key drivers of the quarter's results. Fiscal 2027 Guidance Fiscal 2027 guidance initiated: revenue expected in the range of $2.05 billion to $2.09 billion, growth of 5 to 8 percent, and adjusted EPS expected in the range of $8.90 to $9.35, an 8 to 11 percent growth range, with more improvement expected in the back half of the year. Strong balance sheet and capital returns highlighted, with full year operating cash flow of $471 million (up 41 percent), free cash flow of $393 million (up 39 percent), net leverage improved to 0.5x, and $238 million returned to shareholders via share repurchases in fiscal 2026, with $662 million remaining under the $750 million repurchase program. Conclusion In summary, Covista (NYSE:CVSA) shares rose approximately 13.46 percent to $140.98 at last closing, driven by a fiscal fourth quarter beat and fiscal 2027 guidance topping analyst expectations. These are the verified facts from the earnings release and market data. Whether the rally proves durable may depend on continued enrollment growth at Walden and Chamberlain and progress on the company's capital return program. FAQs. Q: Why did Covista (CVSA) shares rise? A: Shares rose about 13.46 percent after the company beat fiscal fourth quarter estimates on both EPS and revenue and issued fiscal 2027 guidance above analyst expectations. Q: How much did CVSA move and from what level? A: CVSA advanced $16.72 per share, or about 13.46 percent, from a prior close of $124.26 to $140.98 at last closing. Q: What is Covista's fiscal 2027 guidance? A: The company guided fiscal 2027 revenue to a range of $2.05 billion to $2.09 billion and adjusted EPS to a range of $8.90 to $9.35. Q: How much has Covista returned to shareholders? A: The company returned $238 million to shareholders via share repurchases in fiscal 2026, with $662 million remaining under its $750 million repurchase program. Download Free Report - Explore 3 Stock Ideas & Industry Insights Unlock 3 stock ideas and key industry insights in its free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice. All investments involve risk - consider independent advice before making any investment decisions. Disclaimer:

Covista Inc reported strong fourth-quarter and full-year results for 2026, exceeding guidance with revenue growth of 9.3% to $1.954 billion and adjusted earnings per share up 23.7% to $8.25. The company achieved record enrollment of 100,000 students across its platforms, marking 12 consecutive quarters of enrollment growth. Walden saw enrollment increase 14% to nearly 55,000 students, whilst Chamberlain posted its second consecutive quarter of positive growth, up 1.6%. Full-year free cash flow surged 39% to $393 million. Covista returned $238 million to shareholders through share repurchases, reducing shares outstanding by 20%. The company expanded its adjusted EBITDA margin by 100 basis points to 26.7% for the full year. For fiscal 2027, Covista expects revenue between $2.050 billion and $2.090 billion, with adjusted EPS ranging from $8.90 to $9.15.

Covista, America's largest healthcare educator, has appointed Emily C. Chiu and Leslie Storms to its Board of Directors, effective 17 August 2026. The appointments come as the company launches Purpose at Scale, its three-year growth strategy addressing healthcare workforce challenges. Chiu, former CEO of fintech company Novo Platform, previously held executive roles at Block Inc., co-founding its open-source platform and leading Cash App product development. She also co-founded education ventures recognised for flexible degree programmes. Storms serves as Chief Operating Officer at National Veterinary Associates, overseeing more than 1,300 animal hospitals. She previously spent nearly two decades at Johnson & Johnson in senior MedTech leadership positions. With these additions, 10 of Covista's 12 directors will be independent. The company serves over 100,000 students through five accredited institutions.